Upfront surgery for advanced ovarian cancer failed to improve overall survival (OS) versus interval debulking but did improve ...

Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

One woman's story of literal strength illustrates how ovarian cancer symptoms can be missed—and the lighthearted recovery ...

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

Corcept Therapeutics’ relacorilant, a selective glucocorticoid receptor antagonist (SGRA), is emerging as a novel therapeutic ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Around one in 10 women will develop ovarian cysts at some point during their lives, and while the prospect of a cyst growing ...